Mark J Levis, Mehdi Hamadani, Brent Logan, Richard J Jones, Anurag K Singh, Mark Litzow, John R Wingard, Esperanza B Papadopoulos, Alexander E Perl, Robert J Soiffer, Celalettin Ustun, Masumi Ueda Oshima, Geoffrey L Uy, Edmund K Waller, Sumithra Vasu, Melhem Solh, Asmita Mishra, Lori Muffly, Hee-Je Kim, Jan-Henrik Mikesch, Yuho Najima, Masahiro Onozawa, Kirsty Thomson, Arnon Nagler, Andrew H Wei, Guido Marcucci, Nancy L Geller, Nahla Hasabou, David Delgado, Matt Rosales, Jason Hill, Stanley C Gill, Rishita Nuthethi, Denise King, Heather Wittsack, Adam Mendizabal, Steven M Devine, Mary M Horowitz, Yi-Bin Chen
PURPOSE: Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with acute myeloid leukemia (AML) harboring an internal tandem duplication mutation of FLT3 ( FLT3-ITD ) AML. These patients are routinely treated with a FLT3 inhibitor after HCT, but there is limited evidence to support this. Accordingly, we conducted a randomized trial of post-HCT maintenance with the FLT3 inhibitor gilteritinib (ClinicalTrials.gov identifier: NCT02997202) to determine if all such patients benefit or if detection of measurable residual disease (MRD) could identify those who might benefit...
March 12, 2024: Journal of Clinical Oncology